Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Buy" by Analysts

Key Points

• Amneal Pharmaceuticals has received a consensus rating of "Buy" from five analysts, with an average target price of $11.60.
• Institutional investors now own 31.82% of Amneal's stock, with notable increases from several hedge funds in the first quarter.
• The company's recent earnings report showed an EPS of $0.19, exceeding expectations, despite a revenue shortfall of $695.42 million.

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $11.60.

A number of research analysts recently weighed in on AMRX shares. Wall Street Zen cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price target on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Amneal Pharmaceuticals by 5,975.0% in the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after acquiring an additional 3,107 shares in the last quarter. Headlands Technologies LLC bought a new position in Amneal Pharmaceuticals in the 1st quarter valued at $31,000. Amalgamated Bank raised its stake in shares of Amneal Pharmaceuticals by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $52,000. Finally, Straightline Group LLC acquired a new stake in Amneal Pharmaceuticals in the fourth quarter valued at $92,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX traded down $0.06 on Friday, hitting $8.12. 595,348 shares of the company's stock were exchanged, compared to its average volume of 1,671,091. The firm's 50-day moving average is $7.88 and its 200 day moving average is $7.96. The company has a market capitalization of $2.54 billion, a PE ratio of -202.57 and a beta of 1.06. Amneal Pharmaceuticals has a 1-year low of $6.50 and a 1-year high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 188.26% and a negative net margin of 0.46%. The business had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. On average, analysts anticipate that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.